Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00242918 · ClinicalTrials.gov registry record · Phase 2

Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer

A Phase 2 study of Prostate Cancer, sponsored by Benaroya Research Institute.

Completed
Registry status
Phase 2
Development phase
29
Enrollment target
1
Study location

NCT00242918 is a Phase 2 study of Prostate Cancer that has completed, run by Benaroya Research Institute. The registered enrollment target is 29 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00242918, a Phase 2 study of Prostate Cancer, has completed, sponsored by Benaroya Research Institute.

COMPLETED
Registry status
Phase 2
Development phase
29 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the safety and effectiveness of the combination of docetaxel and ZD1839 on destroying prostate cancer before removal of the prostate.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG docetaxel
  • DRUG ZD1839

Study Locations (1)

Washington

  • Virginia Mason Medical Center - Seattle

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2003-05
Est. Completion 2007-11
Phase Phase 2

Sponsor

Benaroya Research Institute

28 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00242918

The ClinicalTrials.gov registry entry for NCT00242918 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Benaroya Research Institute, which has 28 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which docetaxel is the first listed.

NCT00242918 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT00242918 about?

NCT00242918 is a clinical study titled "Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer". The purpose of this study is to determine the safety and effectiveness of the combination of docetaxel and ZD1839 on destroying prostate cancer before removal of the prostate.

What is the current status of trial NCT00242918?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2003-05. Estimated completion is 2007-11.

What conditions does trial NCT00242918 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT00242918?

The interventions under investigation include: docetaxel (DRUG), ZD1839 (DRUG).

Who is sponsoring clinical trial NCT00242918?

This trial is sponsored by Benaroya Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00242918 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Washington

All trials with a study site in Washington

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.